Recent Updates
Recently added Catalysts
TMDX Positive Sentiment

TransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

Key Takeaway: TransMedics Group, Inc. announced they will report their financial results for the third quarter of 2025 on October 29, 2025. The results will be released after market close, and a conference call will follow at 4:30 p.m. ET. TransMedics specializes in organ transplant therapy, particularly in improving the viability and preservation of donor organs.
Price reaction · baseline $111.23 (2025-10-14 close) · hit after-hours · clean, no other TMDX news in the window
day 0 close · peak
+1.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • TransMedics is transforming organ transplant therapy.
  • The company is a leader in portable extracorporeal warm perfusion.
  • Technologies developed may increase the utilization of donor organs.

Full Press Release Details

ANDOVER, Mass. , Oct. 15, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2025 after market close on Wednesday, October 29, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
Investors interested in listening to the conference call may do so by dialing (844) 676-6010 for domestic callers or (412) 634-6944 for international callers and ask to be joined into the TransMedics call. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/ .
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Frequently Asked Questions

When will TransMedics release Q3 2025 financial results?

TransMedics will announce its Q3 2025 financial results on October 29, 2025.

What time is the conference call for financial results?

The conference call will start at 4:30 p.m. ET on October 29, 2025.

How can I listen to the TransMedics conference call?

To listen, call (844) 676-6010 for domestic or (412) 634-6944 for international access.

Where can I find the webcast of the event?

The webcast will be available in the 'Investors' section of TransMedics' website.

What is the focus of TransMedics Group, Inc.?

TransMedics specializes in organ transplant therapy, improving organ preservation and assessment.

Last updated: Oct 15, 2025